Paris, Saturday January 2018

Leriche syndrome: tips, tricks and results, why my option is the best?

OPEN AORTO BIFEMORAL BYPASS

Y. Tshomba

Vascular Surgery, "Università Vita-Salute"

Scientific Institute San Raffaele

Milan, Italy

Disclosures

Nothing To Declare

TASC II Recommendations

Surgery is the treatment of choice for type D lesions

(Treatment of aortoiliac lesions - Recommendation 36)



Norgen et al, EJVES 2007

OSR Open Series: 1993-2017: 269 cases

Distal Occlusion (161 pts.)

Juxtarenal Occlusion (108 pts.)



#1. Aorto Bifemoral Bypass: 142 cases



Transperitoneal



Retroperitoneal

Metanalysis on 5,358 patients

Primary Patency

OPEN*	ENDO	
94.8%	86.0%	(1 year)
86.0%	80.0%	(2 years)
82.7%	71.4%	(3 years)



Indes et al, JEVT 2013

Open Series OSR 1993-2017: 269 cases

Distal Occlusion (161 pts.)



Juxtarenal Occlusion (108 pts.)



Complex Anatomy





Supracoeliac Clamping



Suprarenal Clamping & Endarterectomy

Bilateral Renal Clamping



LRV section



IMA clamp

Technical Challenge

Endarterectomy extended to the renal arteries



#1. Aorto Bifemoral Bypass: 52 cases

Associated renal bypass in 8/52 cases









Associatd Renal Arteries Occlusion

Improved renal function or hypertension control in 68% o cases



Juxtarenal Occlusion After Kissing Stenting



Surgical Bailout



Thrombectomy



Aorto Bifemoral Bypass





Aorto Bifemoral Bypass

OSR Series '93 -'17: 194 cases

Primary Patency: 95.1%

Mean FU 128 ± 16 months

Distal Occlusion : 142	N (%)
Mortality	2 (1.4)
Cardiac Complications	5 (3.5)
Renale Failure (ARD > 2)	6 (4.2)
Juxtarenal Occlusion: 52	**N (%)**
Mortality	2 (3.8)
Cardiac Complications	4 (7.7)
Renal Failure (ARD > 2)	6 (11.5)

#2. Extra-Anatomic Bypass



Axillo-femoral



Thoraco-femoral

Axillo-Femoral Bypass: 36 Cases

Elderly, Unfit, ↓ FE, COPD



Thoraco-Femoral Bypass: 8 cases

Young, Hostile Abdomen



Extra-Anatomic Bypass

OSR Series '93 -'17: 44 cases

Primary Patency: 83.5%

Mean FU: 136 ± 13 months

Axillofemoral: 36	N (%)
Mortality	0
Cardiac Complications	2 (5.5)
Renal Complic (ARD > 2)	3 (8.3)
Thoracofemoral: 8	**N (%)**
Mortality	0
Cardiac Complications	0
Renal Failure (ARD > 2)	1 (12.5%)

#3. Patch Endarterectomy

Young, Limited Disease, ↓ Risk Of Infection




Coral Reef

Coral Reef



Coral Reef



AB Jabr, [...], et M Malina JVS 2013

Coral Reef: Chimney Graft



AB Jabr, [...], et M Malina JVS 2013

Embolic Risk









Our First Choice: Open Surgery



Endarterectomy & Renal Perfusion



Patch Aortoplasty



Extensive Disease: Visceral Rotation



Aortic Exposure



Endarterectomy



Visceral Perfusion



Patch Aortoplasty



Patch Endarterectomy

OSR Series '93 -'17: 31 cases

Primary Patency: 97.1%

Mean FU 114 ± 13 Months

Distal Occlusion: 9	N (%)
Mortality	0
Cardiac Complications	0
Renal Failure (ARD > 2)	0
Juxtarenal Occlusion: 22	**N (%)**
Mortality	1 (4.5)
Cardiac Complications	1 (4.5)
Renal Failure (ARD > 2)	3 (13.6)

Conclusions

Aorto-Iliac Occlusive Disease

ENDOVASCULAR APPROACH

- First choice in most cases (even TASC C & D)

Conclusions

Aorto-Iliac Occlusive Disease

OPEN APPROACH

- First choice in total occlusion > 4 cm
- First choice when renal arteries plane & visceral arteries are involved

Conclusions

Aorto-Iliac Occlusive Disease

OPEN APPROACH

- Customized procedures
- Failed endovascular procedures
- Still unmatched long-term patency
- Continuous results improvements (Custodiol, Dexmedetomidine, cPAP ...)

Show Me Better Options!